SynthesisSystematic reviews2025
The effects of Gegen Qinlian decoction and its main constituents on glucolipid metabolic disorders in diabetes: an overview of systematic reviews and meta-analysis.
Synthesis in Systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Currently, an increasing number of individuals diagnosed with diabetes mellitus (DM) are opting for combined functional substances in edible plant products, like herbal prescription or traditional Chinese medicine (TCM), to enhance the efficacy of blood glucose and lipid profile control. Among various TCM-included treatments available, Gegen Qinlian decoction (GQD) is frequently utilized. Nevertheless, the efficacy and safety of GQD and its main constituents (berberine, puerarin, etc.) in managing glucolipid metabolic disorders (GLMD) in DM remain under considerable debate. This overview aims to provide a concise summary of the key findings from systematic review and meta-analysis (SRMAs) on GQD and its main constituents for GLMD in DM, while also assessing the methodological quality of these reviews. A comprehensive search of online databases was conducted with no language restrictions, covering the period from inception to February 20th, 2025. The methodological quality, risk of bias, and strength of evidence of those included SRMAs were accessed. Overlapping randomized controlled trials (RCTs) were excluded, and the results of included meta-analysis were summarized. After screening, 35 studies matching the inclusion criteria were identified. The current evidence indicated that GQD, berberine, and puerarin appeared to be effective in improving the anti-diabetes role. As for blood lipid profile, it is indicated that GQD and berberine intervention could effectively reduce total cholesterol (TC), total triglycerides (TG), low-density lipoprotein (LDL-c) and increase high-density lipoprotein (HDL-c). Consequently, further high-quality primary studies are imperative to establish a more conclusive understanding of GQD and its main constituents for GLMD in DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.